{
    "root": "30b94d78-0158-ff43-e063-6294a90a030b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20250319",
    "ingredients": [
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X"
        }
    ],
    "indications": "Sertraline tablets are indicated for the treatment of the following\n \n  [See\n  \n   Clinical Studies (14)]\n \n  :\n\n \n                  \n                     Major depressive disorder (MDD)\n                     Obsessive-compulsive disorder (OCD)\n                     Panic disorder (PD)\n                     Posttraumatic stress disorder (PTSD)\n                     Social anxiety disorder (SAD)\n                     Premenstrual dysphoric disorder (PMDD)",
    "contraindications": "­Indication Starting Dosage Maximum Dosage MDD (2.1) 50 mg per day 200 mg per day OCD (2.1) 25 mg per day (ages 6-12) 50 mg per day (ages ≥ 13) 200 mg per day PD, PTSD, SAD (2.1) 25 mg per day 200 mg per day PMDD (2.2) continuous dosing 50 mg per day 150 mg per day PMDD (2.2) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only If inadequate response to starting dosage, titrate in 25-50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) See Full Prescribing Information for titration in PMDD ( 2.2 ) Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) When discontinuing sertraline, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions": "Sertraline 25 mg Tablets: Light Green film coated Modified oval biconvex tablets debossed with\n \n  Ion the left Side of bisect and\n \n  Gon the right Side of bisect on one Side and\n \n  “212”on other\n\n \n                  NDC 69097-833-02 Bottles of 30\n                  NDC 69097-833-05 Bottles of 90\n                  NDC 69097-833-07 Bottles of 100\n                  NDC 69097-833-12 Bottles of 500\n                  Sertraline 50 mg Tablets: Light Blue film coated Modified oval biconvex tablets debossed with\n \n  Ion the left side of bisect and\n \n  Gon the right side of bisect on one side and “\n \n  213”on other\n\n \n                  NDC 69097-834-02 Bottles of 30\n                  NDC 69097-834-05 Bottles of 90\n                  NDC 69097-834-07 Bottles of 100\n                  NDC 69097-834-12 Bottles of 500\n                  Sertraline 100 mg Tablets: Light Yellow film coated Modified oval biconvex tablets debossed with\n \n  Ion the left side of bisect and\n \n  Gon the right side of bisect on one side and\n \n  “214”on other\n\n \n                  NDC 69097-835-02 Bottles of 30\n                  NDC 69097-835-05 Bottles of 90\n                  NDC 69097-835-07 Bottles of 100\n                  NDC 69097-835-12 Bottles of 500\n                  Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].",
    "adverseReactions": "Sertraline is contraindicated in patients:\n                  \n                     Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [See\n   \n    Warnings and Precautions (5.2),\n   \n    Drug Interactions (7.1)]\n  \n   .\n \n  \n                     Taking pimozide\n  \n   [\n   \n    See Drug Interactions (7.1)]\n  \n   .\n \n  \n                     With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema)\n  \n   [See\n   \n    Adverse Reactions (6.1,\n   \n    6.2)]."
}